418 related articles for article (PubMed ID: 11550301)
1. Primary and secondary glioblastomas: from concept to clinical diagnosis.
Kleihues P; Ohgaki H
Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
[TBL] [Abstract][Full Text] [Related]
2. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
3. Phenotype vs genotype in the evolution of astrocytic brain tumors.
Kleihues P; Ohgaki H
Toxicol Pathol; 2000; 28(1):164-70. PubMed ID: 10669004
[TBL] [Abstract][Full Text] [Related]
4. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
5. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
6. Genetic pathways to primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751
[TBL] [Abstract][Full Text] [Related]
7. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
8. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas.
Biernat W; Tohma Y; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 1997 Oct; 94(4):303-9. PubMed ID: 9341929
[TBL] [Abstract][Full Text] [Related]
9. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
[TBL] [Abstract][Full Text] [Related]
11. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
Das A; Tan WL; Teo J; Smith DR
J Neurooncol; 2002 Nov; 60(2):117-25. PubMed ID: 12635658
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
[TBL] [Abstract][Full Text] [Related]
14. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
15. Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences.
Saxena A; Shriml LM; Dean M; Ali IU
Oncogene; 1999 Feb; 18(6):1385-90. PubMed ID: 10022821
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of molecular alterations in microdissected archival gliomas.
Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
[TBL] [Abstract][Full Text] [Related]
17. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.
Fujisawa H; Reis RM; Nakamura M; Colella S; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 2000 Jan; 80(1):65-72. PubMed ID: 10653004
[TBL] [Abstract][Full Text] [Related]
20. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
Biernat W; Kleihues P; Yonekawa Y; Ohgaki H
J Neuropathol Exp Neurol; 1997 Feb; 56(2):180-5. PubMed ID: 9034372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
